Tarsus Pharmaceuticals Inc (NASDAQ:TARS)’s traded shares stood at 1.14 million during the last session, with the company’s beta value hitting 1.00. At the close of trading, the stock’s price was $46.65, to imply an increase of 0.31% or $0.14 in intraday trading. The TARS share’s 52-week high remains $51.59, putting it -10.59% down since that peak but still an impressive 66.56% since price per share fell to its 52-week low of $15.60. The company has a valuation of $1.77B, with an average of 0.93 million shares in intraday trading volume over the past 10 days and average of 716.52K shares over the past 3 months.

Analysts have given a consensus recommendation of Buy for Tarsus Pharmaceuticals Inc (TARS), translating to a mean rating of 1.30. Of 4 analyst(s) looking at the stock, 0 analyst(s) give TARS a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -1.04.

Tarsus Pharmaceuticals Inc (NASDAQ:TARS) trade information

After registering a 0.31% upside in the last session, Tarsus Pharmaceuticals Inc (TARS) has traded red over the past five days. The 5-day price performance for the stock is -0.30%, and 24.10% over 30 days. With these gigs, the year-to-date price performance is 130.37%. Short interest in Tarsus Pharmaceuticals Inc (NASDAQ:TARS) saw shorts transact 8.16 million shares and set a 11.42 days time to cover.

The extremes give us $61 and $63 for target low and target high price respectively. As such, TARS has been trading -35.05% off suggested target high and -30.76% from its likely low.

Tarsus Pharmaceuticals Inc (TARS) estimates and forecasts

Looking at statistics comparing Tarsus Pharmaceuticals Inc share performance against respective industry, we note that the company has outperformed competitors. Tarsus Pharmaceuticals Inc (TARS) shares are 20.92% up over the last 6 months, with its year-to-date growth rate higher than industry average at 19.70% against 16.90%. Revenue is forecast to grow 20.84% this quarter before jumping 25.85% for the next one. The rating firms project that company’s revenue will grow 893.92% compared to the previous financial year.

Revenue forecast for the current quarter as set by 4 analysts is 56.87M. Meanwhile, for the current quarter, a total of 3 analyst(s) estimate revenue growth to 61.53M.Earnings reports from the last fiscal year show that sales brought in 13.08M and 27.61M respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 334.91% before jumping 122.82% in the following quarter.

TARS Dividends

Tarsus Pharmaceuticals Inc has its next earnings report out in December. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Tarsus Pharmaceuticals Inc (NASDAQ:TARS)’s Major holders

Tarsus Pharmaceuticals Inc insiders hold 8.77% of total outstanding shares, with institutional holders owning 119.35% of the shares at 130.82% float percentage. In total, 119.35% institutions holds shares in the company, led by RTW INVESTMENTS, LP. As of 2024-06-30, the company held over 3.41 million shares (or 9.6669% of shares), all amounting to roughly $92.75 million.

The next major institution holding the largest number of shares is BLACKROCK INC. with 3.27 million shares, or about 9.254% of shares outstanding. As of the market price on 2024-06-30, these shares were worth $88.79 million.